TY - JOUR T1 - Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment JF - Anticancer Research JO - Anticancer Res SP - 1305 LP - 1311 VL - 37 IS - 3 AU - MIRKO D'ONOFRIO AU - SARA CINGARLINI AU - SILVIA ORTOLANI AU - STEFANO CROSARA AU - RICCARDO DE ROBERTIS AU - PAOLA VALLERIO AU - ELISABETTA GREGO AU - VALENTINA CIARAVINO AU - ANDREA RUZZENENTE AU - LUCA LANDONI AU - ALDO SCARPA AU - CLAUDIO BASSI AU - GIAMPAOLO TORTORA Y1 - 2017/03/01 UR - http://ar.iiarjournals.org/content/37/3/1305.abstract N2 - Aim: To evaluate modifications of perfusional parameters assessed by perfusion computed tomography (P-CT) of liver metastases (LM) from pancreatic neuroendocrine tumors (PanNETs) during everolimus treatment. Patients and Methods: All patients with LMs from G1-2 PanNETs undergoing everolimus treatment between January 2013 and January 2015 were prospectively evaluated with P-CT at baseline, and after 2 and 4 months of therapy. Size, perfusion, blood volume (BV), peak enhancement intensity (PEI) and time to peak for each lesion were calculated. Results: A total of 33 LMs in nine patients with G1-2 PanNETs were prospectively evaluated: 23/33 (69.7%) were responders, 10/33 (30.3%) were non-responders. Among perfusional parameters, only numerical peak enhancement intensity values significantly differed between the two groups at baseline (p=0.043). BV increase was the most significant perfusional modification identifying responding lesions, even at an early stage of treatment, with a high positive predictive value (89.47%). Conclusion: P-CT seems to be useful for prediction of response to everolimus of LMs from PanNETs. ER -